Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells

被引：31

作者：

Grandjenette, Cindy ^{[1
,2
]}

Kennel, Anne ^{[1
,2
]}

Faure, Gilbert C. ^{[1
,2
]}

Bene, Marie C. ^{[1
,2
]}

Feugier, Pierre ^{[3
]}

机构：

[1] Nancy Univ, Fac Med, Lab Immunol, EA3441,IFR 111, F-54500 Vandoeuvre Les Nancy, France

[2] CHU Nancy, F-54500 Vandoeuvre Les Nancy, France

[3] CHU Nancy, Serv Hematol Adulte, F-54500 Vandoeuvre Les Nancy, France

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 09期

关键词：

TLR; B-CLL; imiquimod; ODN;

D O I：

10.3324/haematol.10975

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This study reports that B-chronic lymphocytic leukemia (B-CLL) cells display the same pattern of toll-like receptors (TLRs) proteins expression as normal B-cells, yet with overexpression of TLR9. Furthermore, TLR7 and TLR9 appear to be functional and liable to respond to specific ligands, respectively imidazoquinolines and CpG-ODN thus potentially opening new therapeutic approaches.

引用

页码：1279 / 1281

页数：3

共 10 条

[1] Toll-like receptors: critical proteins linking innate and acquired immunity [J].

Akira, S ;

Takeda, K ;

Kaisho, T .

NATURE IMMUNOLOGY, 2001, 2 (08) :675-680

[2] The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells [J].

Bourke, E ;

Bosisio, D ;

Golay, J ;

Polentarutti, N ;

Mantovani, A .

BLOOD, 2003, 102 (03) :956-963

[3] Primary cutaneous CD30+T-cell lymphoma responsive to topical imiquimod (Aldara®) [J].

Didona, B ;

Benucci, R ;

Amerio, P ;

Canzona, F ;

Rienzo, O ;

Cavalieri, R .

BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (06) :1198-1201

[4] Topical immunomodulation in dermatology: Potential of Toll-like receptor agonists [J].

Hengge, UR ;

Ruzicka, T .

DERMATOLOGIC SURGERY, 2004, 30 (08) :1101-1112

[5] B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides [J].

Jahrsdorfer, B ;

Mühlenhoff, L ;

Blackwell, SE ;

Wagner, M ;

Poeck, H ;

Hartmann, E ;

Jox, R ;

Giese, T ;

Emmerich, B ;

Endres, S ;

Weiner, GJ ;

Hartmann, G .

CLINICAL CANCER RESEARCH, 2005, 11 (04) :1490-1499

[6] Use of CpG oligodeoxynucleotides as immune adjuvants [J].

Klinman, DM ;

Currie, D ;

Gursel, I ;

Verthelyi, D .

IMMUNOLOGICAL REVIEWS, 2004, 199 (01) :201-216

[7] CpG motifs in bacterial DNA and their immune effects [J].

Krieg, AM .

ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 :709-760

[8] Innate immunity: The virtues of a nonclonal system of recognition [J].

Medzhitov, R ;

Janeway, CA .

CELL, 1997, 91 (03) :295-298

[9] Immunomodulatory effects of toll-like receptor-7 activation on chronic lymphocytic leukemia cells [J].

Spaner, DE ;

Shi, Y ;

White, D ;

Mena, J ;

Hammond, C ;

Tomic, J ;

He, L ;

Tomai, MA ;

Miller, RL ;

Booth, J ;

Radvanyi, L .

LEUKEMIA, 2006, 20 (02) :286-295

[10] Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the toll-like receptor-7/8 agonist, imiquimod [J].

Spaner, DE ;

Miller, RL ;

Mena, J ;

Grossman, L ;

Sorrenti, V ;

Shi, YH .

LEUKEMIA & LYMPHOMA, 2005, 46 (06) :935-939

← 1 →